A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)
Trial details
- Registry ID
- NCT05606614
- Drugs studied
- TSHA-102
TrialRedline tracks 2 clinical trials sponsored by Taysha Gene Therapies, Inc.: 2 Phase 3.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)NCT05606614 | TSHA-102 | Active not recruiting | 2031-06Estimated |
| Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett SyndromeNCT07480564 | TSHA-102 | Active not recruiting | 2031-06Estimated |
Names as written in the registry records.
NCT07480564 · Taysha Gene Therapies, Inc.
Before: Estimated. After: Actual.
Before: 3 participants (planned). After: 4 participants (actual).
Before: Recruiting. After: Active not recruiting.
NCT05606614 · Taysha Gene Therapies, Inc.
Before: Estimated. After: Actual.
Before: 15 participants (planned). After: 17 participants (actual).
Before: Recruiting. After: Active not recruiting.
NCT07480564 · Taysha Gene Therapies, Inc.
Before: Not yet recruiting. After: Recruiting.